DALLAS / Nov 25, 2024 / Business Wire / Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day on December 3, 2024 at 4:30 p.m. ET.
The R&D Day will focus on the development of FB102 across autoimmune indications and will feature key thought leaders in celiac disease, vitiligo and alopecia areata including Prof. Jason Tye-Din MD, PhD, Head of Celiac Research at the Walter and Eliza Hall Institute, Prof. Christopher Ma MD, MPH, FRCPC, academic gastroenterologist at the Cumming School of Medicine, University of Calgary and Prof. David Rosmarin, MD, Chair of the Department of Dermatology at the School of Medicine, Indiana University.
Use the link below to register for the event: https://lifescievents.com/event/fortebiorx/
About Forte
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
| Last Trade: | US$11.48 |
| Daily Change: | 0.92 8.71 |
| Daily Volume: | 155,823 |
| Market Cap: | US$142.700M |
September 15, 2025 August 14, 2025 June 24, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
